September 20, 2017 7:10 PM ET

Biotechnology

Company Overview of FORMA Therapeutics, Inc.

Company Overview

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically-driven diseases. The company’s drug discovery engine deploys screening and structure-based approaches across various families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. It has a strategic partnership with Celgene Corporation. FORMA Therapeutics, Inc. was formerly known as Forma Pharmaceuticals, Inc. and changed its name to FORMA Therapeutics, Inc. in February 2008. The company was incorporated in 2007 and is based in Watertown, Massachusetts. The company has an additional chemistry operation in Branford, Connecticut. FORMA Therapeutics, ...

500 Arsenal Street

Suite 100

Watertown, MA 02472

United States

Founded in 2007

Phone:

617-679-1970

Fax:

617-679-1977

Key Executives for FORMA Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Co-Founder and Director
President of Research & Development
Age: 57
Head of Biomolecular Screening and Executive Director
Executive Vice President and Head of FORMA Therapeutics Ventures
Compensation as of Fiscal Year 2017.

FORMA Therapeutics, Inc. Key Developments

Celgene Corporation Exercises Option to Extend Strategic Collaboration Scope and Term with Forma Therapeutics

FORMA Therapeutics announced that Celgene Corporation has exercised its option, pursuant to the 2014 collaboration arrangement, to extend its strategic collaboration with FORMA by entering into a second collaboration agreement to evaluate additional therapeutic candidates across important emerging target families in the areas of protein homeostasis, inflammation & immunology, and neurodegeneration. Upon execution of this agreement, FORMA received an upfront cash payment of $195 million and Celgene was granted an option to license ex-U.S. rights to select current and future drug candidates through October 1, 2019. Celgene will assume responsibility for all global development activities and costs for in-licensed drug candidates after completion of Phase 1 clinical trials. Under the agreement, FORMA will be eligible to receive milestone payments for licensed drug candidates if certain development, regulatory and sales milestones are achieved. FORMA retains U.S. rights to all such licensed assets, including responsibility for manufacturing and commercialization in their territory. For products not licensed to Celgene, FORMA will maintain worldwide rights. In addition, also pursuant to the 2014 collaboration arrangement, Celgene retains the option to enter into one additional collaboration agreement, during which Celgene will have the exclusive option to acquire FORM, including the U.S. rights to all Celgene-licensed programs, and worldwide rights to other unencumbered, wholly-owned programs within FORMA at that time.

Forma Therapeutics, Inc Enters into an Agreement with Celgene Corporation

Forma Therapeutics, Inc. has entered into an agreement with Celgene Corporation, to advance innovative drugs trageting protein homeostasis. Pursuant to the agreement, Forma Therapeutics and Celgene added two additional objectives; which Forma Therapeutics received a two payments from Celgene. Under the agreement, Forma Therapeutics will discover compounds through its drug discovery team. Celgene will evaluate selected targets and lead assets in protein homeostasis pathways during the pre-clinical phase. Based on such evaluation, Celgene will have the right to obtain exclusive licenses with respect to the development and commercialization of multiple drug candidates outside of the US, in exchange for research and early development payments of up to USD 200 million to Forma Therapeutics. Under the terms, Forma Therapeutics is incentivized to advance the full complement of drug candidates through Phase I, while Celgene will be responsible for all further global clinical development for each licensed candidate. Forma Therapeutics is eligible to receive USD 315 million in potential payments based upon development, regulatory and sales objectives for the first ex-US License. Forma Therapeutics is also eligible to receive potential payments for successive licenses, which escalate for productivity increasing up to a maximum of USD 430 million per program. The partnership enables Forma Therapeutics and Celgene to bring new drugs against new targets and address unmet medical needs in the treatment of many cancers.

FORMA Therapeutics, Inc. Presents at East/West CEO Conference, Jan-08-2017 01:30 PM

FORMA Therapeutics, Inc. Presents at East/West CEO Conference, Jan-08-2017 01:30 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: Steven Tregay, Co-Founder, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact FORMA Therapeutics, Inc., please visit www.formatherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.